ENTITY
Samsung Biologics

Samsung Biologics (207940 KS)

524
Analysis
Health Care • South Korea
Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.
more
bullish•Samsung Biologics
•31 Oct 2025 19:56•Broker

Samsung Biologics (207940 KS/Buy)Spin-Off Likely to Unlock Additional Value

We raise our target price for Samsung Biologics to W1,600,000 (from W1,400,000), which is based on the sum of the values of the CDMO business...

Logo
591 Views
Share
•19 Jun 2026 07:53•Broker

[2H26 Outlook] Pharma/BiotechCatalysts for a biotech rebound

Biotech stocks performed well early this year, driven by optimism surrounding the government's KOSDAQ 3,000 target and supportive fund flows...

Logo
119 Views
Share
•22 Jan 2026 09:55•Broker

Mirae Asset Minutes [2026: Volume 2]Biweekly Strategy Meeting Recap

Driven by surging power demand from data centers, new capacity additions are accelerating across large-scale nuclear power plants, SMRs, and gas...

Logo
172 Views
Share
•08 Jan 2026 08:04•Broker

Mirae Asset Minutes [2026: Volume 1]Biweekly strategy meeting recap

Hyundai Motor Group (HMG) is set to announce its AI robotics strategy on Jan. 6 and is expected to appoint an advanced vehicle platform division...

Logo
182 Views
Share
•11 Dec 2025 03:25•Broker

Mirae Asset Minutes [2025: Volume 23]Biweekly strategy meeting recap

While rising memory prices could modestly weigh on global IT device sales in 2026, we note that memory chips’ share of smartphone BoM costs is only...

Logo
261 Views
Share
x